Table 2 Clinical outcomes between 1G-DES and 2G-DES at 2 years.

From: Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients

Outcomes

Normoglycemia

Group A1

1G-DES

(n = 482)

Group A2

2G-DES

(n = 3191)

Log-rank

Unadjusted

HR (95% CI)

p value

Adjusteda

HR (95% CI)

p value

POCOs

41 (8.6)

193 (6.7)

0.098

1.328 (0.948–1.861)

0.099

1.216 (0.854–1.730)

0.278

All-cause death

22 (4.6)

80 (2.7)

0.025

1.705 (1.063–2.734)

0.027

1.504 (0.914–2.474)

0.109

Cardiac death

17 (3.6)

59 (1.9)

0.027

1.825 (1.064–3.131)

0.029

1.487 (0.838–2.639)

0.176

Re-MI

8 (1.7)

42 (1.5)

0.675

1.175 (0.551–2.505)

0.676

1.180 (0.532–2.619)

0.665

All-cause death or MI

27 (5.6)

116 (4.0)

0.088

1.438 (0.945–2.187)

0.090

1.307 (0.843–2.026)

0.232

Any repeat revascularization

17 (3.6)

85 (3.1)

0.444

1.225 (0.728–2.063)

0.444

1.118 (0.645–1.938)

0.692

Stent thrombosis (probable or definite)

7 (1.5)

15 (0.5)

0.009

3.015 (1.266–7.616)

0.013

3.262 (1.226–8.678)

0.018

Outcomes

Prediabetes

Group B1

1G-DES

(n = 767)

Group B2 2G-DES

(n = 4438)

Log-rank

Unadjusted

HR (95% CI)

p value

Adjustedb HR (95% CI)

p value

POCOs

91 (12.0)

371 (8.9)

0.007

1.372 (1.091–1.726)

0.007

1.369 (1.044–1.720)

0.012

All-cause death

43 (5.6)

185 (4.4)

0.121

1.299 (0.932–1.810)

0.122

1.350 (0.939–1.845)

0.110

Cardiac death

34 (4.5)

140 (3.3)

0.098

1.370 (0.942–1.993)

0.100

1.364 (0.916–1.963)

0.132

Re-MI

19 (2.5)

80 (2.0)

0.305

1.299 (0.787–2.142)

0.306

1.293 (0.780–2.137)

0.316

All-cause death or MI

52 (6.8)

258 (6.1)

0.467

1.117 (0.829–1.505)

0.468

1.114 (0.824–1.502)

0.483

Any repeat revascularization

46 (6.3)

144 (3.6)

0.001

1.780 (1.277–2.481)

0.001

1.795 (1.280–2.518)

0.001

Stent thrombosis (probable or definite)

14 (1.8)

29 (0.7)

0.001

2.806 (1.483–5.311)

0.002

2.637 (1.370–5.077)

0.004

Outcomes

Diabetes

Group C1 1G-DES

(n = 779)

Group C2

2G-DES

(n = 4238)

Log-rank

Unadjusted

HR (95% CI)

p value

Adjustedc

HR (95% CI)

p value

POCOs

107 (13.9)

410 (10.3)

0.003

1.373 (1.110–1.699)

0.003

1.331 (1.070–1.657)

0.010

All-cause death

50 (6.5)

189 (4.7)

0.037

1.390 (1.018–1.899)

0.038

1.534 (1.115–2.112)

0.009

Cardiac death

42 (5.4)

144 (3.5)

0.012

1.544 (1.095–2.178)

0.013

1.700 (1.195–2.448)

0.003

Re-MI

24 (3.2)

105 (2.8)

0.474

1.176 (0.754–1.832)

0.475

1.318 (0.833–2.085)

0.237

All-cause death or MI

64 (8.3)

296 (7.4)

0.377

1.129 (0.862–1.480)

0.378

1.290 (0.977–1.703)

0.073

Any repeat revascularization

51 (6.9)

160 (4.3)

0.001

1.661 (1.212–2.276)

0.002

1.673 (1.211–2.313)

0.002

Stent thrombosis (probable or definite)

16 (2.1)

40 (0.9)

0.007

2.189 (1.226–3.909)

0.008

2.065 (1.100–3.876)

0.024

  1. POCOs patient-oriented composite outcomes defined as a composite of all-cause deaths, Re-MI or any repeat revascularization, Re-MI recurrent myocardial infarction, LVEF left ventricular ejection fraction, DBP diastolic blood pressure, CPR cardiopulmonary resuscitation, PCI percutaneous coronary intervention, hs-CRP high-sensitivity-C-reactive protein, HDL high-density lipoprotein, LDL low-density lipoprotein, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blockers, IRA infarct-related artery, RCA right coronary artery, ACC/AHA American College of Cardiology/American Heart Association, IVUS intravascular ultrasound, OCT optical coherence tomography, FFR fractional flow reserve.
  2. aAdjusted by male, age, CPR on admission, primary PCI, PCI within 24hours, hypertension, peak troponin-I, aspirin, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker, ACEI, ARB, lipid lowering agent, ACC/AHA type B1/C lesions, 1-vessel disease, stent length (p vales of these covariates were < 0.05 or having predictive values).
  3. bAdjusted by male, age, DBP, cardiogenic shock, CPR on admission, primary PCI, PCI within 24 h, hs-CRP, triglyceride, HDL-cholesterol, aspirin, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker, lipid lowering agents, ACC/AHA type C lesions, 1-vessel disease, ≥ 3-vessel disease, FFR, stent length, number of stent (p vales of these covariates were < 0.05 or having predictive values).
  4. cAdjusted by male, age, cardiogenic shock, CPR on admission, PCI within 24hours, previous MI, peak troponin-I, hs-CRP, total cholesterol, LDL-cholesterol, aspirin, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker, ACEI, ARB, lipid lowering agent, IRA (RCA), ACC/AHA type B1/C lesions, OCT, FFR, stent length (p vales of these covariates were < 0.05 or having predictive values).
Back to article page